Evidence map›Paper›PMID 33713197›Full record

ReviewArchivum immunologiae et therapiae experimentalis2021

Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus.

Wen-Yan Tang, Jia-Hua Liu, Chun-Jin Peng, Yao Liao, Jie-Si Luo, Xi Sun, Yan-Lai Tang, Xue-Qun Luo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. [Regulatory effects of mesenchymal stem cells on B1 cells and Tfh cells in children with systemic lupus erythematosus].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Stem cell-based therapy for systemic lupus erythematous.Journal of translational autoimmunity · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Hematopoiesis during Ontogenesis, Adult Life, and Aging.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wen-Yan TangDepartment of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Jia-Hua LiuDepartment of Parasitology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Chun-Jin PengDepartment of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Yao LiaoDepartment of Parasitology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Jie-Si LuoDepartment of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Xi SunDepartment of Parasitology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China. sunxi2@mail.sysu.edu.cn.
Yan-Lai TangDepartment of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China. tangylai@mail.sysu.edu.cn.
Xue-Qun LuoDepartment of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China. l-xuequn@126.com.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNMinistry of Education of the People's Republic of China · CN

Funding

81600111 8160011181600112 81600112
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a rare, heterogeneous autoimmune and autoinflammatory disease that affects both sexes and all races, although this disease exhibits its highest incidence/prevalence among the black population and shows a predilection for women of reproductive age. Although SLE has no cure, treatment can help decrease its signs and symptoms. Thus, we should focus primarily on personalized treatment. Mesenchymal stem/stromal cells (MSCs), which are multipotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes, and myoblasts, among other cell types, are potential candidates for use in a promising strategy to treat severe and refractory SLE. MSCs have an immunomodulatory function that can suppress the proliferation and activities of many immune cells, such as T lymphocytes, B lymphocytes, natural killer cells, macrophages and dendritic cells. Substantial progress has recently been made in MSC therapy, and experimental and clinical data suggest that such a therapy is a promising strategy for the treatment of severe and refractory SLE. In this review, we highlight the effects of MSCs on different immune cell types, describe the mechanisms underlying MSC-mediated immunoregulation, and discuss the treatment of SLE with MSCs from different sources in various animal models and clinical applications.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsClinical Trials as TopicDisease Models, AnimalHumansImmunotherapyLupus Erythematosus, SystemicMesenchymal Stem CellsRecurrenceSecondary PreventionSeverity of Illness IndexTreatment OutcomeApplicationMesenchymal stem cellsSystemic lupus erythematosusTransplantation

Identifiers

PMID33713197
OpenAlexW3134717708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.